Philip Tsai Biography and Net Worth

CTO of Immunome

Prior to joining Immunome, Dr. Tsai spent 21 years at Seagen and then Pfizer (following the acquisition of Seagen in December 2023) in positions of increasing responsibility. Most recently, he was the SVP of Technical Development, responsible for end-to-end development of biologics and drug-linker manufacturing processes, analytics, and drug products. Over the past two decades, he led a productive CMC development organization to advance Seagen’s pipeline, including commercialization of its products. Dr. Tsai began his biotech career at Biogen, where he spent seven years optimizing biologics manufacturing processes.

Dr. Tsai earned his M.S. degree and a PhD in Chemical Engineering with a minor in Biology from California Institute of Technology and a B.S. degree from the University of Illinois, Champaign Urbana.

What is Philip Tsai's net worth?: The estimated net worth of Philip Tsai is at least $259,074.00 as of March 24th, 2025. Tsai owns 33,300 shares of Immunome stock worth more than $259,074 as of May 14th. This net worth approximation does not reflect any other assets that Tsai may own. Learn More about Philip Tsai's net worth.
How do I contact Philip Tsai?: The corporate mailing address for Tsai and other Immunome executives is , , . Immunome can also be reached via phone at 610-321-3700 and via email at investors@immunome.com. Learn More on Philip Tsai's contact information.
Has Philip Tsai been buying or selling shares of Immunome?: Philip Tsai has not been actively trading shares of Immunome during the past quarter. Most recently, on Monday, March 24th, Philip Tsai bought 12,300 shares of Immunome stock. The stock was acquired at an average cost of $8.42 per share, with a total value of $103,566.00. Following the completion of the transaction, the chief technology officer now directly owns 33,300 shares of the company's stock, valued at $280,386. Learn More on Philip Tsai's trading history.
Who are Immunome's active insiders?: Immunome's insider roster includes Jean Bienaime (Director), Jack Higgins (Insider), Robert Lechleider (Insider), Michael Lefenfeld (Director), Michael Rapp (Director), Max Rosett (CFO), Purnanand Sarma (CEO), Clay Siegall (CEO), Philip Tsai (CTO), and Bruce Turner (Insider). Learn More on Immunome's active insiders.
Are insiders buying or selling shares of Immunome?: In the last twelve months, Immunome insiders bought shares 9 times. They purchased a total of 418,262 shares worth more than $3,425,760.18. In the last twelve months, insiders at the sold shares 2 times. They sold a total of 17,904 shares worth more than $279,313.12. The most recent insider tranaction occured on March, 26th when CEO Clay B Siegall bought 137,100 shares worth more than $999,459.00. Insiders at Immunome own 8.6% of the company. Learn More about insider trades at Immunome.
Information on this page was last updated on 3/26/2025.

Philip Tsai Insider Trading History at Immunome

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/24/2025	Buy	12,300	$8.42	$103,566.00	33,300
11/21/2024	Buy	21,000	$9.43	$198,030.00	21,000

Philip Tsai Buying and Selling Activity at Immunome

Immunome Company Overview

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Today's Range

Now: $7.97

$7.42

$8.07

50 Day Range

MA: $7.71

$5.56

$9.34

2 Week Range

Now: $7.97

$5.15

$16.81

Volume

915,066 shs

Average Volume

918,613 shs

Market Capitalization

$693.49 million

P/E Ratio

N/A

Dividend Yield

N/A

Philip Tsai Biography and Net Worth

What is Philip Tsai's net worth?

How do I contact Philip Tsai?

Has Philip Tsai been buying or selling shares of Immunome?

Who are Immunome's active insiders?

Are insiders buying or selling shares of Immunome?